{"DataElement":{"publicId":"3441909","version":"1","preferredName":"Melanoma Neoplasm Pathologic M Stage Stratification Stage","preferredDefinition":"Classification of patients into M stage of the TMN staging system for a malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.","longName":"MELANOMA_MSTG","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"3441906","version":"1","preferredName":"Melanoma Neoplasm Pathologic M Stage Stratification","preferredDefinition":"Classification of patients into M stage of the TMN staging system for a malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.","longName":"2206800v1.0:3441904v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2206800","version":"1","preferredName":"Melanoma Neoplasm","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that contain melanin.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C3224:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-04EC-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3441904","version":"1","preferredName":"Pathologic M Stage Stratification","preferredDefinition":"Caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  M refers to the presence of metastasis.:The process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"C25610:C25727:C25689","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F3C92-ED13-5858-E040-BB89AD4304B3","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-04-23","modifiedBy":"ONEDATA","dateModified":"2012-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F3C92-ED24-5858-E040-BB89AD4304B3","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-04-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3119693","version":"1","preferredName":"Melanoma Pathologic M Stage","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that contain melanin.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004_Caused by or altered by or manifesting disease or pathology._One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"3119693v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"MX","valueDescription":"MX Stage Finding","ValueMeaning":{"publicId":"2580840","version":"1","preferredName":"MX Stage Finding","longName":"2580840","preferredDefinition":"Status of distant metastasis cannot be assessed in accordance with TNM classification system guidelines. (from AJCC 6th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MX TNM Finding","conceptCode":"C48704","definition":"A distant metastasis TNM finding indicating that the status of distant metastasis cannot be assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-08D5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-13","modifiedBy":"ONEDATA","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B233257-CA0E-2CDD-E040-BB89AD436CCB","beginDate":"2010-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-11","modifiedBy":"ONEDATA","dateModified":"2010-07-11","deletedIndicator":"No"},{"value":"M0","valueDescription":"M0 Stage Finding","ValueMeaning":{"publicId":"2580838","version":"1","preferredName":"M0 Stage Finding","longName":"2580838","preferredDefinition":"No evidence of distant metastasis, in accordance with TNM classification system guidelines. (from AJCC 6th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M0 TNM Finding","conceptCode":"C48699","definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-08D3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-13","modifiedBy":"ONEDATA","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B233257-CA18-2CDD-E040-BB89AD436CCB","beginDate":"2010-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-11","modifiedBy":"ONEDATA","dateModified":"2010-07-11","deletedIndicator":"No"},{"value":"M1a","valueDescription":"Metastasis to skin, subcutaneous tissues, or distant lymph nodes","ValueMeaning":{"publicId":"2576769","version":"1","preferredName":"Metastasis to skin, subcutaneous tissues, or distant lymph nodes","longName":"2576769","preferredDefinition":"Metastasis to skin, subcutaneous tissues, or distant lymph nodes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8EE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-07","modifiedBy":"ALAIS","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AE170EA-C49A-64C6-E040-BB89AD4303FE","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA","dateModified":"2010-07-08","deletedIndicator":"No"},{"value":"M1b","valueDescription":"Metastasis to lung","ValueMeaning":{"publicId":"2576770","version":"1","preferredName":"Metastasis to lung","longName":"2576770","preferredDefinition":"Metastasis to lung","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-07","modifiedBy":"ALAIS","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AE170EA-C4A5-64C6-E040-BB89AD4303FE","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA","dateModified":"2010-07-08","deletedIndicator":"No"},{"value":"M1c","valueDescription":"Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum lactic dehydrogenase","ValueMeaning":{"publicId":"2576771","version":"1","preferredName":"Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum lactic dehydrogenase","longName":"2576771","preferredDefinition":"Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum lactic dehydrogenase","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8F0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-07","modifiedBy":"ALAIS","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AE170EA-C4B0-64C6-E040-BB89AD4303FE","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA","dateModified":"2010-07-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3119692","version":"1","preferredName":"Melanoma Pathologic M Stage Stage","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that contain melanin.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004:Pathologic; caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  M refers to the presence of metastasis.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C3224:C25610:C25727:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AE170EA-C473-64C6-E040-BB89AD4303FE","latestVersionIndicator":"Yes","beginDate":"2010-07-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA","dateModified":"2010-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC:American Joint Committee on Cancer Cancer Staging Manual, 7th Ed., 2009","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AE170EA-C484-64C6-E040-BB89AD4303FE","latestVersionIndicator":"Yes","beginDate":"2010-07-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"REEVESD","dateModified":"2010-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Location of metastatic disease","type":"Preferred Question Text","description":"Location of metastatic disease","url":null,"context":"CTEP"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F3C92-ED36-5858-E040-BB89AD4304B3","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-04-23","modifiedBy":"SBR","dateModified":"2013-10-25","changeDescription":" Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}